Former Sanofi UK head joins Pertinax Pharma as chairman

14 November 2017
nigel_brooksby_large

UK-based Pertinax Pharma says that Nigel Brooksby, a former chairman of Sanofi UK, has been appointed as chairman of the company, where he will drive the commercialization of the company’s Pertinax.

His chief responsibilities will be to assist in corporate, strategic and business development moves into its commercialization phase following the launch last month of Pertinax, a slow-release technology that provides a continual release of chlorhexidine (CHX).

This unique technology which enablescontrolled and sustained release of the antimicrobial, chlorhexidine (CHX) has wide ranging potential applications, spanning the wound care, medical device, dental and veterinary markets. Pertinax Pharma - originally a spin out from the University of Bristol - was established in April 2015.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical